Evidence map›Paper›PMID 39904839›Full record

ArticleThe AAPS journal2025

Development of a PBPK Model for Lamotrigine which Incorporates Metabolism by UGT2B10: Impact of UGT2B10 Poor Metabolizer Phenotype and Pregnancy.

Iain Gardner, Aki T Heikkinen, Lloyd Wei Tat Tang, Kimberly Lapham, Theunis C Goosen

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Iain GardnerCertara Predictive Technologies, 1 Concourse Way, Level 2-Acero, Sheffield, S1 2BJ, UK. iain.gardner@certara.com.ORCID 0000-0002-4811-8513
Aki T HeikkinenCertara Predictive Technologies, 1 Concourse Way, Level 2-Acero, Sheffield, S1 2BJ, UK.
Lloyd Wei Tat TangPharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Groton, Connecticut, USA.
Kimberly LaphamPharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Groton, Connecticut, USA.
Theunis C GoosenPharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Groton, Connecticut, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An updated physiologically based pharmacokinetic (PBPK) model was developed for lamotrigine by incorporating a component of metabolism due to a UDP-glucuronyltransferase (UGT) 2B isozyme. This was assigned to UGT2B10 based on recent in vitro data in our laboratory demonstrating metabolism of lamotrigine by this isozyme (Tang et al. AAPS J 26:107, 2024). The PBPK model developed in this work was able to reasonably recapitulate the exposure of lamotrigine after single (IV and Oral) and multiple (Oral) doses. The predicted/observed maximal plasma concentration (C

Indexed as

AnticonvulsantsGlucuronosyltransferaseLamotrigineMinor Histocompatibility AntigensModels, BiologicalAdministration, OralAdultArea Under CurveComputer SimulationFemaleHumansPhenotypePregnancyAnticonvulsantsGlucuronosyltransferaseLamotrigineMinor Histocompatibility AntigensUGT2B10 protein, humanlamotriginePBPKUGT1A4UGT2B10

Identifiers

PMID39904839

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.